The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38α MAP kinase inhibitor

John Hynes, Hong Wu, Sidney Pitt, Ding Ren Shen, Rosemary Zhang, Gary L. Schieven, Kathleen M. Gillooly, David J. Shuster, Tracy L. Taylor, Xiao Xia Yang, Kim W. McIntyre, Murray McKinnon, Hongjian Zhang, Punit H. Marathe, Arthur M. Doweyko, Kevin Kish, Susan E. Kiefer, John S. Sack, John A. Newitt, Joel C. BarrishJohn Harold Dodd, Katerina Leftheris

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

A novel structural class of p38α MAP kinase inhibitors has been identified via iterative SAR studies of a focused deck screen hit. Optimization of the lead series generated 6e, BMS-640994, a potent and selective p38α inhibitor that is orally efficacious in rodent models of acute and chronic inflammation.

Original languageEnglish (US)
Pages (from-to)1762-1767
Number of pages6
JournalBioorganic and Medicinal Chemistry Letters
Volume18
Issue number6
DOIs
StatePublished - Mar 15 2008

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38α MAP kinase inhibitor'. Together they form a unique fingerprint.

Cite this